Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed information regarding the company's regulatory submissions and prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 7, 2024, to May 23, 2025, Savara's defendants failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the defendants' positive statements regarding the company's business and prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Savara are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for November 7, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

LOS ANGELES--(BUSINESS WIRE)--Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SVRA. ...

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) and certain officers. ...

Core Viewpoint - Savara Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between March 4, 2024, and May 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Savara Inc. made false statements regarding the MOLBREEVI Biologics License Application (BLA) for the treatment of pulmonary alveolar proteinosis, indicating insufficient information about its chemistry, manufacturing, and controls [2] - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2] - The public statements made by the defendants were deemed materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, ensuring no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, highlighting its expertise in complex securities litigation [4]

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses exceeding $50,000 in Savara between March 7, 2024, and May 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Savara, with a deadline of November 7, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Savara and its executives made false statements regarding the MOLBREEVI BLA, including insufficient information about its chemistry and manufacturing, which likely affected FDA approval [6]. Group 2: Stock Performance and Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA on May 27, 2025, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share [7]. Group 3: Company Background and Recovery - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995, with offices in multiple states [5]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, alleging misleading statements regarding the company's drug application process [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Savara made false statements about the MOLBREEVI Biologics License Application (BLA), indicating it lacked sufficient information for FDA approval [5]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true information became public [5]. Group 2: Class Action Participation - Investors who purchased Savara securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 7, 2025, to represent the interests of the class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Group 1 - Savara Inc. has been identified as a promising healthcare penny stock, with Guggenheim raising its price target from $8 to $11 while maintaining a Buy rating, following a 16% stock rally year to date [1][2] - The price target increase is supported by positive developments regarding the company's Biologics License Application (BLA), with potential FDA approval expected by mid-next year [2][3] - Savara is transitioning its primary drug manufacturing from GEMA to Fujifilm Diosynth Biotechnologies, which is significant due to Fujifilm's strong FDA track record and new claims indicating a 50% increase in the number of patients in the US with autoimmune pulmonary alveolar proteinosis (aPAP) [3][4] Group 2 - Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, particularly its lead candidate, molgramostim, an inhaled GM-CSF for aPAP [4]

Group 1 - Savara Inc. is facing a class action securities lawsuit as notified by Levi & Korsinsky, LLP [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI [3][4]. Group 1: Allegations Against Savara - The complaint alleges that Savara and its executives made false and misleading statements regarding the MOLBREEVI BLA, specifically that it lacked sufficient information on chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, making previous public statements materially false and misleading [3]. Group 2: Stock Price Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [4]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 in Savara between March 7, 2024, and May 23, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Savara is November 7, 2025 [1].